Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age. Local targets link to admitted publications; unresolved targets remain external evidence.
Incidence of respiratory syncytial virus infection among hospitalized adults, 2017–2020
10.1093/cid/ciab595 · 2022 · External reference
Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices - United States, 2023
10.15585/mmwr.mm7229a4 · 2023 · External reference
Respiratory syncytial virus infection in adults
10.1136/bmj.l5021 · 2019 · External reference
Respiratory syncytial virus-associated hospitalizations among adults with chronic medical conditions
10.1093/cid/ciaa730 · 2021 · External reference
Herpes zoster in the older adult
10.1016/j.idc.2017.07.016 · 2017 · External reference
Risk factors for herpes zoster infection: a meta-analysis
10.1093/ofid/ofaa005 · 2020 · External reference
Burden of herpes zoster in individuals with chronic conditions in the Republic of Korea: a nationwide population-based database study
10.1093/ofid/ofae535 · 2024 · External reference
Unresolved reference
2016 · External reference
Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis
10.1111/irv.13031 · 2023 · External reference
Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)
2008 · External reference
Healthy ageing: herpes zoster infection and the role of zoster vaccination
10.1038/s41541-023-00757-0 · 2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Development, current status, and remaining challenges for respiratory syncytial virus vaccines
10.3390/vaccines13020097 · 2025 · External reference
Respiratory syncytial virus infections in adults: a narrative review
10.1016/s2213-2600(24)00255-8 · 2024 · External reference
Optimal timing of vaccination: a narrative review of integrating strategies for COVID-19, influenza, and respiratory syncytial virus
10.1007/s40121-025-01135-0 · 2025 · External reference
Use of respiratory syncytial virus vaccines in adults aged ≥60 years: updated recommendations of the Advisory Committee on Immunization Practices—United States, 2024
10.15585/mmwr.mm7332e1 · 2024 · External reference
Unresolved reference
External reference
Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?
10.1186/s12931-022-02305-1 · 2023 · External reference
A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations
10.1080/14760584.2021.1956906 · 2021 · External reference
Unresolved reference
External reference
Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices—United States, 2022
10.15585/mmwr.mm7103a2 · 2022 · External reference
Randomized, open-label phase 3 study evaluating immunogenicity, safety, and reactogenicity of RSVPreF3 OA coadministered with FLU-QIV-HD in adults aged≥65
10.1007/s40121-024-00985-4 · 2024 · External reference
Immunogenicity, reactogenicity, and safety of AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based candidate vaccine (RSVPreF3 OA) when co-administered with a seasonal quadrivalent influenza vaccine in older adults: results of a phase 3, open-label, randomized controlled trial
10.1093/cid/ciad786 · 2026 · External reference
Safety and immunogenicity of respiratory syncytial virus prefusion F protein vaccine when co-administered with adjuvanted seasonal quadrivalent influenza vaccine in older adults: a phase 3 randomized trial
10.1093/cid/ciae365 · 2024 · External reference
Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: an overview
10.1016/j.vaccine.2024.02.035 · 2024 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: a randomized trial
10.1016/j.vaccine.2018.05.110 · 2018 · External reference
The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial
10.1016/j.jinf.2021.12.033 · 2022 · External reference
No immunological interference or safety concerns when adjuvanted recombinant zoster vaccine is coadministered with a Coronavirus Disease 2019 mRNA-1273 booster vaccine in adults aged 50 years and older: a randomized trial
10.1093/cid/ciad361 · 2023 · External reference
Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older
10.1093/infdis/jix481 · 2017 · External reference
The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: a randomized trial
10.1016/j.vaccine.2019.08.001 · 2019 · External reference
